Photocure ASA

Earnings Release • May 6, 2019

Photocure ASA: Expanded role for Cysview® in treating bladder cancer patients - presented at the 2019 AUA Annual Meeting

Photocure ASA: Expanded role for Cysview® in treating bladder cancer patients - presented at the 2019 AUA Annual Meeting

OSLO, Norway, May 6, 2019 - Photocure ASA (OSE: PHO) today announced key data

presented at the 2019 American Urological Association (AUA) Annual Meeting in

Chicago.  Session presentations and a poster presentation discussed Blue Light

Cystoscopy (BLCT) with Cysview.

BLCT with Cysview® was featured in several sessions at the AUA meeting,

including:

·  Blue Light Cystoscopy for the diagnosis of Bladder Cancer

Dr. Badrinath Konety, University of Minnesota

·  Surgical Techniques: Tips & Tricks: Oncology

Dr. Yair Lotan, UTSW, presented on BLC with Cysview for surveillance

Dr. Yair Lotan M.D., Professor of Urology, UT Southwestern Medical Center and

the lead author on a new Consensus paper (https://rebrand.ly/AUAPR-Consensus)

for use of BLC with Cysview in the office setting said, "Reaching a broad

consensus on the optimal use of BLC with Cysview is a significant milestone.

There is considerable, high-quality data that supports the use of BLC with

Cysview, and the Consensus Statement provides practical information on

incorporating flexible BLC into practice." He went on to say, "Recurrence is

often found during surveillance cystoscopies which are typically done using a

flexible cystoscope, so it is significant that there is consensus on how to use

Cysview in that setting. We expect this advancement will enhance detection in

the outpatient setting and improve patient management."

There was also a poster presentation of data from the Nordic Blue Light Flexible

Cystoscopy registry that showed BLC in the clinic (outpatient) setting may

reduce the need for an operating room (OR) visit for a follow-up transurethral

resection of bladder tumor (TURBT).

Poster highlights include:

· 75% of patients reported that BLC with Cysview added value to their disease

maintenance

· 27% cited the main advantage of the procedure as "stronger confidence in

confirming/refuting a suspicious lesion"

· 95% of patients said they preferred the outpatient procedure over a TURBT in

the operating room

Overall, there was high interest in Blue Light Cystoscopy (BLCT) with Cysview at

the Photocure booth and the adjacent KARL STORZ booth. Of the over 16, 500

attendees at this year's AUA Meeting, there were many urologists interested in

this state-of-the-art drug/device technology for the detection and management of

bladder cancer.

"To date, over a half million bladder cancer patients worldwide have been

diagnosed or treated using BLC with Cysview," says Dan Schneider, President and

CEO of Photocure. "We're proud to have impacted so many lives so far. In the

U.S. alone, last year's 45% increase in the number of medical facilities that

offer BLC with Cysview demonstrates our commitment to improving access for both

urologists and bladder cancer patients."

To learn more about Cysview and see video case studies of it in action, visit

BLC with Cysivew Video Case Studies (https://rebrand.ly/AUAPR-CaseStudies)

About Bladder Cancer

Bladder cancer is the sixth most commonly diagnosed cancer in the US and is the

fourth most common cancer found in men in the US.(1,2) It is estimated that

there will be 80,470 new cases of bladder cancer and 17,670 deaths due to

bladder cancer in 2019.(3) Risk factors for bladder cancer include advancing

age, cigarette smoking, occupational exposure to dyes, tar, rubber and solvent,

and chronic bladder irritation and infections.(4) Bladder cancer is one of the

most expensive cancers to manage. It is estimated that upwards of $5.71 billion

will be spent on bladder cancer in the US in the year 2020.(5)

Bladder cancer is classified into two types, non-muscle invasive bladder cancer

(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of

invasion in the bladder wall.(4) NMIBC is in the inner layer of cells.(3) These

cancers are the most common (75%) of all bladder cancer cases and include the

subtypes carcinoma in situ (CIS), Ta and T1 lesions.(5) MIBC is when the cancer

has grown into deeper layers of the bladder wall.(2) These cancers, including

subtypes T2, T3 and T4, are more likely to spread and are harder to treat.(6)

About Hexvix®/Cysview® (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that is selectively taken up by tumor cells in the

bladder making them glow bright pink during Blue Light Cystoscopy (BLC). BLC

with Hexvix/Cysview improves the detection of tumors and leads to more complete

resection, fewer residual tumors and better management decisions.

Cysview is the tradename in the US and Canada, Hexvix is the tradename in all

other markets. Photocure is commercializing Cysview/Hexvix directly in the US

and the Nordic region and has strategic partnerships for the commercialization

of Hexvix/Cysview in Europe, Canada, Australia and New Zealand. Please refer to

Commercial Partners (https://bit.ly/2wzqSQQ) for further information on our

commercial partners.

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, which makes

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com or www.cysview.com.

For more information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Tel: + 1-609 759-6515

Email: ds@photocure.com

Erik Dahl

CFO

Photocure ASA

Tel: +4745055000

Email: ed@photocure.com

1.National Cancer Institute. SEER Stat Facts: Bladder Cancer 2017.

https://seer.cancer.gov/statfacts/html/urinb.html. Accessed on January 25, 2019.

2. American Cancer Society's (ACS) publication. Cancer Facts and Figures 2017:

Special Section - Rare Cancers in Adults, and the ACS website.

https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and

-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures

-2017.pdf. Accessed on March 25, 2019.

3. American Cancer Society. Key Statistics for Bladder Cancer 2019.

https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Accessed

on March 25, 2019.

4. American Cancer Society. Bladder Cancer.

http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer

-additional. Accessed on March 25, 2019.

5. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost

of cancer care in the United States: 2010-2020. J Natl Cancer Inst.

2011;103(2):117-28.

6. Pulver D, Schoenberg M, Pulver F. Bladder Cancer: A Patient-Friendly Guide to

Understanding Your Diagnosis and Treatment Options. Patient-Friendly Publishing;

2017.